227 related articles for article (PubMed ID: 28696236)
1. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; McCarthy MW; Kovanda LL; Zaw MH; Hussain K; Shaikh N; Maung BBW; Sekhon NK; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696236
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Naing E; Kavaliauskas P; Barat S; Borroto-Esoda K; Azie N; Angulo D; Walsh TJ
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179521
[TBL] [Abstract][Full Text] [Related]
4. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
5. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
7. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.
Petraitiene R; Petraitis V; Bacher JD; Finkelman MA; Walsh TJ
Med Mycol; 2015 Aug; 53(6):558-68. PubMed ID: 26129890
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Petraitis V; Petraitiene R; Sarafandi AA; Kelaher AM; Lyman CA; Casler HE; Sein T; Groll AH; Bacher J; Avila NA; Walsh TJ
J Infect Dis; 2003 Jun; 187(12):1834-43. PubMed ID: 12792859
[TBL] [Abstract][Full Text] [Related]
9. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.
Katragkou A; McCarthy M; Meletiadis J; Petraitis V; Moradi PW; Strauss GE; Fouant MM; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2014 Nov; 58(11):6934-7. PubMed ID: 25136021
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
[TBL] [Abstract][Full Text] [Related]
13. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
14. In vitro combination therapy with isavuconazole against Candida spp.
Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V
Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571
[TBL] [Abstract][Full Text] [Related]
15. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
Hope WW; Petraitis V; Petraitiene R; Aghamolla T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4879-86. PubMed ID: 20713673
[TBL] [Abstract][Full Text] [Related]
16. Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.
Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Moradi PW; Sussman-Straus GE; Naing E; Kovanda LL; Finkelman MA; Walsh TJ
Med Mycol; 2021 Feb; 59(2):189-196. PubMed ID: 33313821
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
18. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
19. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.
Petraitis V; Petraitiene R; Solomon J; Kelaher AM; Murray HA; Mya-San C; Bhandary AK; Sein T; Avila NA; Basevicius A; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Apr; 50(4):1510-7. PubMed ID: 16569871
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
